메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

The 138th Canton Fair is Set to Open in Guangzhou on Octob…

GUANGZHOU, China, Oct. 13, 2025 -- The 138th China Import and Export Fair (Canton Fair) is set to open in Guangzhou from October 15 to November 4, divided into three phases. The fair will maintain its 24-hour online presence to offer global buyers continuous access to Chinese suppliers. With an exhibition area of 1.55 million square meters, this session will feature a record 74,600 booths and more than 32,000 participating enterprises. The 138th Canton Fair marks a new milestone in both scale and innovation. For the first time, more than 10,000 exhibitors hold titles such as &q
- 김갑성 기자
- 2025-10-13 14:42
Lundbeck's bexicaserin receives Breakthrough Therapy D…

[ 메디채널 김갑성 기자 ] Accelerated pathway underscores urgent need for innovative solutions for patients with devastating, childhood-onset epilepsies Novel 5HT2C mechanism designed to reduce drug-resistant seizures in children and adults living with Developmental Epileptic Encephalopathies (DEEs) and improve quality of life for patients and their caregivers1 Dual Breakthrough Therapy Designation (BTD) in China and the U.S. underscores Lundbeck's mission to advance brain health and transform lives of patients with rare neurological diseases VALBY, Denmark, Oct. 13, 2025 -- Lundbeck tod
- 김갑성 기자
- 2025-10-13 14:26
ISTH marks World Thrombosis Day with urgent global call to ac…

[ 메디채널 김갑성 기자 ] Thrombosis is the underlying cause of 1 in 4 deaths worldwide each year. The campaign calls for crucial awareness and prevention. CHARLOTTE, N.C., Oct. 13, 2025 -- The International Society on Thrombosis and Haemostasis (ISTH) today marks World Thrombosis Day, a global movement uniting thousands of partners in more than 120 countries. This year's campaign, "From Head to Toe, Take Control. Prevent Thrombosis. Protect Your Health," calls for greater awareness of thrombosis and action to reduce its burden worldwide. Observed annually on October
- 김갑성 기자
- 2025-10-13 14:00
Singclean Anti-adhesion Technology With Professor Osam…

CAPE TOWN, South Africa, Oct. 13, 2025 -- Singclean Medical, in partnership with Kayan Al-Seha Medical (KSM) and Professor Osama Shawki, successfully made its debut at the FIGO World Congress of Gynecology and Obstetrics 2025, held from October 5–9 at the Cape Town International Convention Centre. Participation at FIGO, marks a key milestone in Singclean's global strategy and growing influence in women's healthcare. Singclean Innovative Anti-adhesion Technology with Professor Osama Shawki at Figo 2025 Professor Osama Shawki's Keynote Highlights Singclean® Adhesio
- 김갑성 기자
- 2025-10-13 13:00
GC Biopharma Secures CMO Rights for Shingles Vaccine from…

YONGIN, South Korea, Oct. 13, 2025 -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed an agreement with Curevo Vaccine to secure contract manufacturing (CMO) rights for amezosvatein (development name: CRV-101), a recombinant shingles vaccine currently under clinical development. Under the terms of the agreement, GC Biopharma will be responsible for producing a portion of the commercial supply of amezosvatein for global markets. The global shingles vaccine market is currently dominated by GSK's Shingrix.
- 김갑성 기자
- 2025-10-13 12:38
Smartee Launches World's First Sleep Aligner Combining Ant…

SHANGHAI, Oct. 13, 2025 -- Smartee Denti-Technology today announced the global launch of the Smartee Sleep Aligners, a clear aligner device designed to help manage obstructive sleep apnoea hypopnoea syndrome (OSAHS) and primary snoring (PS). The new series includes two versions: Smartee SA, which focuses on the treatment of OSAHS and PS, and Smartee SA Plus. The latter can treat OSAHS while simultaneously addressing orthodontic issues. Together, they provide clinicians with an invisible alternative to conventional OSAHS treatment therapies, offering greater comfort and compliance, and improvi
- 김갑성 기자
- 2025-10-13 09:38
Everest Medicines Announces NMPA Approval of IND Applicat…

[ 메디채널 김갑성 기자 ] EVM14 becomes Everest Medicines' internally developed therapeutic mRNA cancer vaccine to receive IND approvals from both China's National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). EVM14, an off-the-shelf therapeutic mRNA cancer vaccine, is developed based on Everest Medicines' proprietary mRNA platform. It is formulated with mRNA encoding 5 tumor-associated antigens (TAAs) and is designed to treat various squamous cell carcinomas. In preclinical studies, EVM14 demonstrated the ability to induce immune memory and prevent tumor
- 김갑성 기자
- 2025-10-13 08:47
Ascletis Selects a Best-In-Class Once-Monthly Subcutaneo…

- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC35 was approximately 14 days, 6-fold longer than tirzepatide, which supports once-monthly subcutaneous (SQ) dosing in humans. - In head-to-head NHP studies, drug exposures of ASC35 intravenous (I.V.) and SQ administration were approximately 80% and 70% greater than tirzepatide I.V. and SQ administration, respectively. - ASC35 was approximately 4-fold more potent than tirzepatide for both GLP-1 receptor (GLP-1R) and GIP receptor (GIPR) in vitro. - ASC35 demonstrated approximately 71% greate
- 김갑성 기자
- 2025-10-13 08:10
Reach Surgical's OMNIBOT Performs First Urology Robotic Teles…

Advancing regional collaboration and surgeon training in remote robotic-assisted surgery SINGAPORE, Oct. 13, 2025 -- Reach Surgical, the Surgical Solutions division of Genesis MedTech, has facilitated the completion of two robotic telesurgeries using its OMNIBOT robotic-assisted system. Operating from Reach Surgical Institute (RSI) in Santiago, Dr. Roberto Vilches and Dr. Marcelo Kerkebe remotely performed a radical prostatectomy and a partial nephrectomy on patients at Meds Medical Center. These procedures mark an important milestone in advancing robotic t
- 김갑성 기자
- 2025-10-13 08:00
C-Ray Therapeutics (Chengdu) Co., Ltd Congratulates Partn…

CHENGDU, China, Oct. 11, 2025 -- C-Ray Therapeutics (Chengdu) Co.,Ltd proudly congratulates its strategic partner, Biokin Pharmaceutical, on receiving implied approval from the National Medical Products Administration (NMPA) for the clinical trial application of [177Lu]-BL-ARC001 Injection, the company's first radiopharmaceutical and a Class 1 innovative biologic. This milestone approval marks Biokin's entry into the fast-growing Radiopharmaceutical Drug Conjugate (RDC) field and reinforces its leadership in large-molecule oncology therapies (ADC/GNC/ARC). The company's flagship asset
- 김갑성 기자
- 2025-10-11 20:45

이전

71 72 73 74 75 76 77 78 79 80

많이 본 기사

최근기사

2025-12-16_TUE

2025-12-15_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 16일 02시 40분